Esperion Therapeutics Inc. [NASDAQ: ESPR] traded at a high on Thursday, posting a 1.92 gain after which it closed the day’ session at $2.66. The company report on February 13, 2024 at 8:00 AM that Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
The results of the trading session contributed to over 2989153 shares changing hands. Over the past one week, the price volatility of Esperion Therapeutics Inc. stands at 7.13% while the volatility over the past one month is 10.88%.
The market cap for ESPR stock reached $453.32 million, with 170.42 million shares outstanding and 169.06 million shares in the current float. Compared to the average trading volume of 6.17M shares, ESPR reached a trading volume of 2989153 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Esperion Therapeutics Inc. [ESPR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $8.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 03, 2024.
The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.24, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 4.41.
How has ESPR stock performed recently?
Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.10. With this latest performance, ESPR shares gained by 3.50% in over the last four-week period, additionally plugging by 73.86% over the last 6 months – not to mention a drop of -53.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 60.29, with the RSI for the last a single of trading hit 64.66, and the three-weeks RSI is set at 58.94 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.30, while it was recorded at 2.60 for the last single week of trading, and 1.56 for the last 200 days.
Esperion Therapeutics Inc. [ESPR]: Deeper insight into the fundamentals
Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.21 and a Current Ratio set at 1.58.
Earnings analysis for Esperion Therapeutics Inc. [ESPR]
With the latest financial reports released by the company, Esperion Therapeutics Inc. posted -0.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.84/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.
Insider trade positions for Esperion Therapeutics Inc. [ESPR]
The top three institutional holders of ESPR stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ESPR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ESPR stock with ownership which is approximately 5.8325%.
